Switch Therapeutics

Switch Therapeutics is revolutionizing RNAi therapies through its innovative Conditionally Activated siRNA (CASi) platform. Their platform combines nucleic acid nanotechnology and RNA interference (RNAi) science to develop novel genetic medicines for the treatment of various diseases. CASi allows for precise control of gene expression, targeting specific cell types and cell states. The platform enables efficient self-delivery and uptake of RNA molecules, improving therapeutic efficacy. CASi can effectively and sustainably reduce the expression of target genes. Switch Therapeutics is primarily focused on developing treatments for neurological conditions, leveraging the potential of CASi to address these complex diseases. They are also exploring the applications of CASi for treating systemic diseases beyond the nervous system. They are advancing multiple programs for the treatment of neurodegenerative diseases, focusing on achieving high CNS potency, long duration, and deep brain distribution.

Jobs: